The MPN method can be useful when traditional bioburden tests won’t work, but it must be clearly understood and carefully implemented.
Seven key trends and events helped make Liquid Biopsy attractive to investors, shareholders, patients, and physicians.
Researchers found that SelectMDx, a test for prostate cancer, had a cost-savings of $1,694 per patient.
Personal Genome Diagnostics received a breakthrough device designation from FDA for the PGDx elio plasma resolve liquid biopsy test.
Blue Earth Diagnostics shines at the 2018 annual meeting of the Society of Nuclear Medicine and Molecular Imaging, with fleshed out results from the LOCATE trial.
Myriad Genetics presented results from a 24-week study that showed Major Depressive Disorder patients were 50% more likely to achieve remission and 30% more likely to respond to treatment using the GeneSight Psychotropic genetic test.
Orion Diagnostica develops Point-of-Care tests and earned about $67 million in sales for its most recent reported year.
Qiagen has developed liquid biopsy panels for prostate and lung cancer and is set to introduce the products at the American Association for Cancer Research annual meeting this week.
Jan Medical partners with U.S. Army to nab a concussion detection indication for BrainPulse technology.